title: [Maximal androgen blockade little influences bone mineral density in prostate cancer patients].
abstract: OBJECTIVE
  To determine the influence of maximal androgen blockade (MAB) on bone mineral density (BMD) in men with prostate cancer.
  
  
  METHODS
  We enrolled 40 men with prostate cancer treated by MAB for 7 to 12 months. We obtained the laboratory results of PSA, testosterone, serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone, measured the BMD of the lumbar spine and femoral neck by dual energy X-ray absorptiometry, recorded pain scores, and compared the results before and after the treatment.
  
  
  RESULTS
  Before MAB treatment, 5 (12.5%) of the patients met the BMD criteria of lumbar spine (L2-4) osteopenia, 8 (20%) lumbar spine (L2-4) osteoporosis, 13 (32.5%) left femoral neck osteopenia, and 15 (37.5%) left femoral neck osteoporosis. The PSA and testosterone levels were decreased from (52.9 +/- 69.9) microg/L and (18.9 +/- 6.5) nmol/L before MAB to (1.5 +/- 1.6) microg/L and (1.9 +/- 1.3) nmol/L after it (P<0.05). There were no statistically significant differences before and after MAB in the levels of serum calcium and phosphorus, 24-h urine calcium and phosphorus, alkaline phosphatase, and parathyroid hormone (P>0.05), nor in the BMD levels of the lumbar spine ([1.1 +/- 0.1] vs [1.1 +/- 0.2] g/cm2) and femoral neck ([0.8 +/- 0.2] vs [0.8 +/- 0.1] g/cm2), nor in the pain score ([0.6 +/- 0.2] vs [0.7 +/- 0.1], P>0.05).
  
  
  CONCLUSIONS
  MAB treatment (range from 7 to 12 months) has no significant influence on BMD in men with prostate cancer, but BMD should be measured before MAB.
authors.affiliation: Wu Jieping Urology Medical Center, Shougang Hospital of Peking University, Beijing 100041, China.
authors.forename: Guo-Feng
authors.initials: GF
authors.lastname: Sun
authors.forename: Bing
authors.initials: B
authors.lastname: Yang
authors.forename: He
authors.initials: H
authors.lastname: Zhu
authors.forename: Ning-Chen
authors.initials: NC
authors.lastname: Li
authors.forename: Yan-Qun
authors.initials: YQ
authors.lastname: Na
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000032:analysis; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000209:etiology; D002118:Calcium / Q000097:blood / Q000652:urine; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000209:etiology; D010281:Parathyroid Hormone / Q000032:analysis; D010758:Phosphorus / Q000652:urine; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013739:Testosterone / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D010281:Parathyroid Hormone; D010758:Phosphorus; D013739:Testosterone; D000469:Alkaline Phosphatase; D002118:Calcium